Blood platelets lack a nucleus. As a result their life span is short and they cannot reproduce themselves. Platelets share these qualities with the red blood cell. Plateยญ lets and red blood cells, nevertheless, serve vital roles in the body. One major function of the platelet is its capacity to aggregate and thereby initiate intravasยญ cular coagulation which often underlies such major diseases as myocardial infarcยญ tion, cerebral infarction, and pulmonary embolism. For this reason in recent years, medical attention has been directed to drugs that inhibit platelet aggregation. Aspirin was the first drug to be proven effective in this area. Since then other drugs that share aspirin's fundamental biochemical action, inhibition of platelet cyclooxygenase, have also been studied. Very recently, ticlopidine, the first of what promises to be a new class of drugs inhibiting platelet aggregation and coagulation via an entirely different biochemical mechanism, has been extenยญ sively studied and clinically shown to be as effective or more effective than aspirin in the prevention of ischemic cardiovascular and cerebrovascular disease
CONTENT
1. Changing Concepts of the Pathophysiology of Cerebral and Myocardial Infarction -- 2. Overview of Ticlopidineโ{128}{153}s Development -- 3. Pharmacodynamics and Pharmacokinetics of Ticlopidine -- 4. Ticlopidineโ{128}{153}s Mechanism of Action on Human Platelets -- 5. Clinical Studies of Stroke Prevention with Ticlopidine in Man -- 6. Clinical Trials of Ticlopidine in Patients with Intermittent Claudication -- 7. Clinical Trials of Ticlopidine in Patients with Coronary Artery Disease -- 8. A Systematic Overview of Randomized Trials of Antiplatelet Agents for the Prevention of Stroke, Myocardial Infarction, and Vascular Death -- 9. An Analysis of the Side Effects of Ticlopidine -- 10. The Role of Ticlopidine in Prevention of Ischemic Stroke: A Benefit-Risk Assessment
